Thavalinh Sphabmixay, MD
Family Medicine · Atwater, CANPI 1841445277
Payments from drug & device makers
Across 171 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$366
- GSK$273
- Johnson & Johnson$238
- Lilly USA, LLC$209
- Pfizer$209
- Novo Nordisk$189
- plus $2K from 25 others
What the payments were for
- Food & beverage$3,039100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 12 | $366 |
| GSK | 15 | $273 |
| Johnson & Johnson | 13 | $238 |
| Lilly USA, LLC | 13 | $209 |
| Pfizer | 13 | $209 |
| Novo Nordisk | 10 | $189 |
| Sanofi-aventis U.S. LLC | 14 | $184 |
| Merck | 12 | $169 |
| Bayer | 10 | $159 |
| Novartis | 8 | $141 |
| AstraZeneca | 8 | $132 |
| Exact Sciences | 4 | $117 |
| Hologic Sales And Service, LLC | 5 | $107 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $99 |
| Avanir Pharmaceuticals, Inc. | 4 | $74 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $63 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Shield Therapeutics Inc | 2 | $36 |
| Gilead | 2 | $32 |
| Corcept Therapeutics | 1 | $28 |
| Organon | 2 | $25 |
| Abbott | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Acadia Pharmaceuticals Inc | 1 | $20 |
| Edwards Lifesciences | 1 | $18 |
| AbbVie | 1 | $17 |
| Scilex Pharmaceuticals Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Urovant Sciences Inc | 1 | $12 |
| Boehringer Ingelheim | 1 | $11 |
How this compares
$3,051 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 68 | $97,418 |
| OzempicSemaglutide | 101 | $93,186 |
| EliquisApixaban | 82 | $80,101 |
| FarxigaDapagliflozin Propanediol | 81 | $77,894 |
| NuplazidPimavanserin Tartrate | 12 | $56,038 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $30,185 |
| RybelsusSemaglutide | 13 | $27,176 |
| XareltoRivaroxaban | 13 | $22,283 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $17,147 |
| MyrbetriqMirabegron | 20 | $12,741 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $10,113 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 309 | $9,219 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $7,905 |
| Atorvastatin Calcium | 517 | $6,975 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $6,948 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $189 | $120,362114 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $11 | $104,36783 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $132 | $88,00799 claims |
| PfizerEliquis, Paxlovid | $209 | $81,48596 claims |
| Acadia Pharmaceuticals IncNuplazid | $20 | $56,03812 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $273 | $41,88263 claims |
| Johnson & JohnsonXarelto | $238 | $22,28313 claims |
| Sanofi-aventis U.S. LLCLantus | $184 | $2,67032 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.
Other family medicine in Atwater
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.